Recommendation of the President – Jardiance (empagliflozin)
On 23 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 154/2024 on the inclusion in reimbursement of the medicinal product Jardiance (empagliflozin) in the indication: type 2 diabetes mellitus, in patients using at least one hypoglycemic drug, with HbA1c ≥7% and very high cardiovascular risk understood as: 1. confirmed cardiovascular disease, or 2. damage to other organs manifested by: proteinuria or left ventricular hypertrophy or retinopathy, or 3. the presence of 3 or more major risk factors among the following: age ≥55 years for men and ≥60 years for women, dyslipidemia, hypertension, smoking, obesity